ArticleBMC pharmacology & toxicology2020
A protein interaction map identifies existing drugs targeting SARS-CoV-2.
Article in BMC pharmacology & toxicology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Unlocking the potential: multimodal AI in biotechnology and digital medicine-economic impact and ethical challenges.NPJ digital medicine · 2025Review
- Integrative multiomics and in silico analysis revealed the role of ARHGEF1 and its screened antagonist in mild and severe COVID-19 patients.Journal of cellular biochemistry · 2022Article
- Smaller reaction volume of triplex taqman real-time reverse transcription-PCR assays for diagnosing coronavirus disease 2019.Journal of clinical laboratory analysis · 2022Article
- Identification of oligosaccharyltransferase as a host target for inhibition of SARS-CoV-2 and its variants.Cell discovery · 2021Article
- Potential drugs against COVID-19 revealed by gene expression profile, molecular docking and molecular dynamic simulation.Future virology · 2021Article
- Article
- Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19.Scientific reports · 2021Article
- Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19.Research square · 2021Article
- Patient-Specific Network for Personalized Breast Cancer Therapy with Multi-Omics Data.Entropy (Basel, Switzerland) · 2021Article
- Present and future treatment strategies for coronavirus disease 2019.Future journal of pharmaceutical sciences · 2021Review
- Rapid growth in the COVID-19 era.MRS bulletin · 2021Review
- Network Controllability-Based Prioritization of Candidates for SARS-CoV-2 Drug Repositioning.Viruses · 2020Article
- Nicotinamide: Oversight of Metabolic Dysfunction Through SIRT1, mTOR, and Clock Genes.Current neurovascular research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere acute respiratory syndrome coronavirus (SARS-CoV-2), an emerging Betacoronavirus, is the causative agent of COVID-19. Angiotensin converting enzyme 2 (ACE2), being the main cell receptor of SARS-CoV-2, plays a role in the entry of the virus into the cell. Currently, there are neither specific antiviral drugs for the treatment or preventive drugs such as vaccines.
methodsWe proposed a bioinformatics analysis to test in silico existing drugs as a fast way to identify an efficient therapy. We performed a differential expression analysis in order to identify differentially expressed genes in COVID-19 patients correlated with ACE-2 and we explored their direct relations with a network approach integrating also drug-gene interactions. The drugs with a central role in the network were also investigated with a molecular docking analysis.
resultsWe found 825 differentially expressed genes correlated with ACE2. The protein-protein interactions among differentially expressed genes identified a network of 474 genes and 1130 interactions.
conclusionsThe integration of drug-gene interactions in the network and molecular docking analysis allows us to obtain several drugs with antiviral activity that, alone or in combination with other treatment options, could be considered as therapeutic approaches against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.